ARTICLE | Clinical News
Ganaxolone: Preliminary Ph II data
January 27, 2017 9:08 PM UTC
Preliminary data from 4 patients with cyclin dependent kinase like 5 (CDKL5) epilepsy in an open-label, U.S. and Italian Phase II trial showed that once-daily doses of up to 1,800 mg/kg oral ganaxolon...
BCIQ Company Profiles
BCIQ Target Profiles